Cargando…

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma

Background: Pheochromocytoma and paraganglioma (PHEO/PGL) are rare neuroendocrine tumors which may cause potentially life-threatening complications, with about a third of cases found to harbor specific gene mutations. Thus, early diagnosis, treatment, and meticulous monitoring are of utmost importan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jha, Abhishek, de Luna, Kristine, Balili, Charlene Ann, Millo, Corina, Paraiso, Cecilia Angela, Ling, Alexander, Gonzales, Melissa K., Viana, Bruna, Alrezk, Rami, Adams, Karen T., Tena, Isabel, Chen, Alice, Neuzil, Jiri, Raygada, Margarita, Kebebew, Electron, Taieb, David, O'Dorisio, M. Sue, O'Dorisio, Thomas, Civelek, Ali Cahid, Stratakis, Constantine A., Mercado-Asis, Leilani, Pacak, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395427/ https://www.ncbi.nlm.nih.gov/pubmed/30854332 http://dx.doi.org/10.3389/fonc.2019.00053

Ejemplares similares

SUN-LB26 Radioligand Theranostics of Endocrine-Related Cancers; A New, Revolutionary Approach
por: Harris, Alan G, et al.
Publicado: (2020)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Pathogenicity and Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL)
por: Maniam, Pavithran, et al.
Publicado: (2018)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

The current status of somatostatin receptors in malignant melanoma.
por: Fletcher, W. S., et al.
Publicado: (1997)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma
por: Patel, Mayank, et al.
Publicado: (2022)

Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging
por: Alrezk, Rami, et al.
Publicado: (2018)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Prospective Analysis of the Impact of (68)Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors
por: Ghobrial, Silvia N., et al.
Publicado: (2020)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study
por: Schovanek, Jan, et al.
Publicado: (2014)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

SDHB and SDHA Immunohistochemistry in Canine Pheochromocytomas
por: Abed, Firas M., et al.
Publicado: (2020)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2016)

Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2017)

Management of Diarrhea in Patients With Carcinoid Syndrome
por: Naraev, Boris G., et al.
Publicado: (2019)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2022)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

Somatic SDHA mutations in paragangliomas in siblings: Case report of 2 cases
por: Huang, Yen-Chun, et al.
Publicado: (2020)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma
por: Vanova, Katerina Hadrava, et al.
Publicado: (2021)

RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective
por: Crona, Joakim, et al.
Publicado: (2018)

Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications()()
por: Imperiale, Alessio, et al.
Publicado: (2015)

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
por: Gelhorn, Heather L., et al.
Publicado: (2016)

MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

A case of Carney triad complicated by renal cell carcinoma and a germline SDHA pathogenic variant
por: Wurth, Rachel, et al.
Publicado: (2021)

A Case of Carney Triad Complicated by Renal Cell Carcinoma and a Germline SDHA Pathogenic Variant
por: Wurth, Rachel, et al.
Publicado: (2021)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Pheochromocytoma and paraganglioma: imaging characteristics
por: Baez, Juan C., et al.
Publicado: (2012)

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
por: Tran, Catherine G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dn30p979l947hlhpdserqkk87e